Overview

PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma

Status:
Unknown status
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Prospective multicenter phase 2 study using PAD and Thal/Dex combination sequentially.
Phase:
Phase 2
Details
Lead Sponsor:
Korean Multiple Myeloma Working Party
Collaborator:
Celgene Corporation
Treatments:
BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Doxorubicin
Liposomal doxorubicin
Thalidomide